About this episode

The episode discusses the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer with expert urologists.

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps00:00 - Introduction01:02 - Risk Stratification07:22 - Upstaging to High Risk10:06 - Calculators and Patient Education15:22 - Specific Tests Use Cases18:50 - Conflicting Biomarker Results21:36 - Adjunct Tests and Counseling24:03 - Recurrence After Chemo Next Steps27:01 - Escalation Deescalation Balance32:48 - Future Research Priorities35:43 - Biology Based Risk Stratification38:03 - Clinical Pearls and Wrap Up --- More about this episodeThe conversation highlights the heterogeneity of…

People in this episode

Host: Dr. Bogdana Schmidt

Guests: Dr. Sunil Patel, Dr. Kristen Scarpato

Topics covered

• bladder cancer
• risk stratification
• pathology interpretation
• diagnostic tools
• treatment decisions

Keywords

• bladder cancer
• risk assessment
• pathology
• diagnostic tools
• treatment outcomes

Sponsors

Johnson & Johnson

More episodes of BackTable Urology

• Ep. 318 Exploring Neuromodulation: Sacral vs Tibial Approaches with Dr. Ken Peters and Dr. Tracey Wilson · July 21, 2026 · 1h 0m
• Ep. 317 Focal Therapy in Prostate Cancer Treatment with Dr. George R. Schade · July 16, 2026 · 48 min
• Ep. 316 Bladder Cancer in the Community: Meeting Patients Where They Are with Dr. Adam J. Gadzinski · July 14, 2026 · 49 min
• Ep. 315 Private Equity's Impact on Urology Practices with Dr. Benjamin Lowentritt · July 10, 2026 · 49 min
• Ep. 314 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis · July 7, 2026 · 52 min
• Ep. 313 Approaches to Pelvic Lymph Node Dissection in Contemporary Prostate Cancer Surgery with Dr. Kristen Greene · June 30, 2026 · 36 min

Explore listener stats, chart rankings, contacts and more on the BackTable Urology podcast page.